explore -WSS

explore

author：explore 2025-09-09 19:28:27 - browse：9

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： NVIDIA and Google execs on the future of AI and drug discovery

WSS

Amid AI frenzy, a top HHS official's quest to create safeguards

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Helping hospitals and community health centers plan for resilience

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Arc Institute generative AI designs new CRISPR systems

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

UCLA team creates talking throat patch for voice disorders

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How many hemophilia patients actually want gene therapy?

After affirmative action ruling, medical educators look to 'holistic review'

Big Tobacco's 'harm reduction': Is it for real, or a sham?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Wearables generate powerful data but its not useful to doctors, yet

Malaria cases in Florida and Texas: Here’s what you need to know

Glen Campbell's doctor discusses his public struggle with Alzheimer's

focus

FDA advisers back CAR

Second House panel advances two

WuXi out of biotech trade group, U.S. and China relations to blame

How many hemophilia patients actually want gene therapy?

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

It's time to retire 'poor historian' from clinicians' vocabularies

knowledge

focus

hotspot

knowledge